Hepatocellular Carcinoma Hepatocellular Carcinoma Transarterial Chemoembolization
Conditions
Interventions
IV NAC -
loading dose: 150 mg/kg/h of NAC over 1 hour,
followed by 12.5 mg/kg/h for 4 hours and continuous infusions of 6.25 mg/kg for 48 hours post-
TACE ,Standard intravenous fluid
acetyl-
cysteine,Normal saline
Sponsors
Faculty of Medicine, Thammasat University
Faculty of Medicine,
Thammasat University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Patients with a diagnosis of hepatocellular carcinoma (HCC) and subjected to treat with chemoembolization (TACE) ( The diagnosis of HCC is based on (American association of liver diseases (AASLD) guidelines 2010) - Age 18-65 years - No contraindication to N-acetyl-cysteine
Exclusion criteria
Exclusion criteria: - Receiving other treatment within 6 months duration (e.g. radiofrequency ablation (RFA) or surgical liver resection) - Having severe underlying illness e.g. ESRD, cardiac disease, AIDS, etc. - Pregnancy or lactation - Receiving possible drug interaction with NAC e.g. Nitroglycerine - Denial to participate the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-embolisation syndrome 72 hours Symptomatic assessment and laboratory investigation | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic decompensation 72 hours Symptomatic assessment and laboratory investigation | — |
Countries
Thailand
Contacts
Public ContactSith Siramolpiwat
Thammasat University
Outcome results
None listed